22:54 , Apr 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma In vitro and mouse studies identified an α-galactosylceramide (α-GalCer)-based antigen that could enhance the antitumor immunity of invariant natural killer T (NKT) cells to treat metastatic melanoma. Chemical synthesis and in vitro binding...
02:15 , Dec 16, 2017 |  BioCentury  |  Product Development

Assessing the BCMA scene

Differences in patient populations and a dearth of clinical outcome data mean it’s too soon to declare bluebird bio Inc.’s anti-BCMA chimeric antigen receptor therapy the leader of the pack of CARs that presented clinical...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
07:00 , Oct 20, 2016 |  BC Innovations  |  Translation in Brief

Killer burn

A Cell Metabolism study argues a type of immune cell, dubbed invariant NK T (iNKT) cell, is responsible for the weight-lowering effects of glucagon-like peptide-1 receptor (GLP-1R; GLP1R) agonists by increasing fat browning and thermogenesis...
07:00 , Jul 28, 2016 |  BC Innovations  |  Tools & Techniques

Best of both worlds

Natural killer (NK) cells aren't the only new class of immune cells attracting attention for immuno-oncology. A group from Baylor College of Medicine has found a subset of natural killer T (NKT) cells, a cell...
07:00 , Apr 28, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: T cell receptor (TCR); CD1D

Cancer INDICATION: T cell lymphoma Mouse and patient sample studies suggest inhibiting TCR signaling with anti-CD1D antibodies or cyclosporine A could help treat T cell lymphomas. In a mouse model of peripheral T cell lymphoma, spleen...
07:00 , May 8, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Inflammatory bowel disease (IBD) CD1D; IL-10; signal transducer and activator of transcription 3 (STAT3) Mouse studies...
07:00 , Sep 26, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Asthma Aspergillus fumigatus asperamide B In vitro and mouse studies suggest inhibiting...
07:00 , Oct 20, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Stroke Adrenergic receptors; CD1D A study in mice suggests antagonizing adrenergic receptors...
07:00 , May 20, 2010 |  BC Innovations  |  Targets & Mechanisms

Waste management for lupus

Systemic lupus erythematosus and other autoimmune diseases are usually viewed as disorders of acquired immunity marked by production of autoantibodies. Now, independent German and Swedish teams have found that components of the innate immune response-neutrophils...